ETN029

ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research.


Cat. No.: EX-A13985	Purity: >98%

	Chemical structure of ETN029

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	912	in-stock
10mg	1450	in-stock
25mg	2250	in-stock
50mg	get quote	in-stock
100mg	get quote	in-stock
1g	get quote	in-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	3066864-32-9
Purity	>98%
Formula	C101H140N22O26S2
Mol Weight	2142.454
Color	White to light yellow
State	Solid
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder 4°C, sealed storage, away from moisture and light; In solvent -20°C, 1 month.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. A. Savinainen, et al. 1153P Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers. Neuroendocrine tumours Volume 35, Supplement 2 S755 September 2024. [2]. Ninatti G, et al. Radioligand Therapy in Cancer Management: A Global Perspective. Cancers (Basel). 2025;17(21):3412. Published 2025 Oct 23. [3]. Ku SY, et al. Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer. Mol Cancer Ther. 2026;25(2):346-354.
CoA	CoA of ETN029

Smiles:	CC(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@H](C(N([C@H](C(N[C@@H]3C(N[C@@H](CC4CCN(CC(O)=O)CC4)C(N[C@@H](CC(N)=O)C(N[C@@H](CC5=CC=C6C=CC=CC6=C5)C(N[C@@H](CCCCNC(CN7CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC7)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N8CCC[C@H]8C(N)=O


		Search